日本熟妇大胆A∨_717午夜伦电影理伦片_天天操私人影院_芃芃大人小皮鞋红绿灯寸止_毛片免费看看_亚洲狠狠久久综合一区二区_亚洲欧美日韩精品综合在线一区二_坤坤戳进别人里面游戏

為眾生謀健康
AI 驅(qū)動 mRNA 創(chuàng)新藥物平臺

One Health For All
AI-Powered mRNA Drug Platform

澄實生物致力于利用人工智能與 mRNA 技術(shù)平臺,開發(fā)針對腫瘤和傳染病的創(chuàng)新療法與疫苗,讓更多患者獲得前沿治療。

TheraRNA leverages AI and mRNA technology platforms to develop innovative therapies and vaccines targeting cancer and infectious diseases.

了解核心技術(shù) Explore our technology
SCROLL
0
授權(quán)專利
Patents Granted
0
SCI 論文
SCI Papers
0
核心團(tuán)隊
Core Team
H100
GPU 算力集群
GPU Cluster
2-8°C
凍干常溫保存
Cold Chain Free
我們的使命
Our mission
澄實生物專注于 AI 驅(qū)動的 mRNA 全棧藥物研發(fā),致力于為全球患者提供更有效、更可及的創(chuàng)新療法。
TheraRNA is committed to AI-driven full-stack mRNA drug development, delivering more effective and accessible therapies to patients worldwide.

我們相信,人工智能與免疫學(xué)的深度融合將徹底改變藥物研發(fā)的范式。從 AI 新生抗原預(yù)測到自研 LNP 遞送系統(tǒng),從 mRNA 分子設(shè)計到 GMP 規(guī)模化量產(chǎn)——澄實生物構(gòu)建了全鏈條自主可控的技術(shù)閉環(huán),打通從算法到產(chǎn)品的完整路徑。

We believe the deep integration of artificial intelligence and immunology will fundamentally transform drug development. From AI neoantigen prediction to proprietary LNP delivery systems, from mRNA molecular design to GMP mass production — TheraRNA has built a fully self-controlled technology closed loop, bridging algorithm to product.

了解更多 Read more
我們的使命 Our Mission
治療領(lǐng)域
Therapeutic areas
聚焦腫瘤免疫治療、耐藥菌感染和動物健康三大領(lǐng)域,以 mRNA 技術(shù)平臺為核心驅(qū)動。
Focused on oncology immunotherapy, drug-resistant bacterial infections, and animal health, powered by our mRNA technology platform.
研發(fā)管線
Pipeline

利用 mRNA 技術(shù)平臺的強(qiáng)大通用性和 AI 算法的高效迭代能力,構(gòu)建覆蓋多適應(yīng)癥的豐富管線。

Leveraging the versatility of mRNA platforms and AI-driven rapid iteration to build a diversified pipeline across multiple indications.

0
在研品種
Pipeline Products
0
三甲醫(yī)院合作
Top Hospital Partners
0
腫瘤客觀緩解率
Oncology ORR
10億
年產(chǎn)能(劑)
Annual Capacity (doses)
查看完整管線Explore our pipeline
新聞動態(tài)
Latest news
了解澄實生物的最新研發(fā)進(jìn)展、合作動態(tài)和行業(yè)資訊。
Stay updated with TheraRNA's latest R&D progress, partnerships, and industry insights.
查看全部新聞View all news